Regeneron Pharmaceuticals' stock loss was below the S&P 500 gain on July 17, 2025.
2 reports, 2 independent
Updated Jul 17
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron Pharmaceuticals' stock loss was below the S&P 500 gain on July 17, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- StockStory3 Reasons to Avoid REGN and 1 Stock to Buy Instead Over the past six months, Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% ga
- Insider MonkeyUBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huyn